MA42665A - Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations - Google Patents

Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Info

Publication number
MA42665A
MA42665A MA042665A MA42665A MA42665A MA 42665 A MA42665 A MA 42665A MA 042665 A MA042665 A MA 042665A MA 42665 A MA42665 A MA 42665A MA 42665 A MA42665 A MA 42665A
Authority
MA
Morocco
Prior art keywords
diantibodies
binding
bispecific monovalent
bispecific
monovalent
Prior art date
Application number
MA042665A
Other languages
English (en)
Inventor
Ralph Alderson
Ezio Bonvini
Gurunadh Reddy Chichili
Ling Huang
Leslie S Johnson
Paul A Moore
Kalpana Shah
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MA42665A publication Critical patent/MA42665A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA042665A 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations MA42665A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
MA42665A true MA42665A (fr) 2018-06-27

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042665A MA42665A (fr) 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Country Status (21)

Country Link
US (1) US20190002563A1 (fr)
EP (1) EP3337507A4 (fr)
JP (1) JP2018523686A (fr)
KR (1) KR20180038045A (fr)
CN (1) CN107921130A (fr)
AU (1) AU2016307955A1 (fr)
CA (1) CA2995709A1 (fr)
CL (1) CL2018000422A1 (fr)
CO (1) CO2018001485A2 (fr)
CR (1) CR20180105A (fr)
EA (1) EA201890443A1 (fr)
EC (1) ECSP18011248A (fr)
HK (1) HK1249423A1 (fr)
IL (1) IL257562A (fr)
MA (1) MA42665A (fr)
MX (1) MX2018001954A (fr)
PE (1) PE20181066A1 (fr)
PH (1) PH12018500363A1 (fr)
TW (1) TW201718652A (fr)
WO (1) WO2017030926A1 (fr)
ZA (1) ZA201800955B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CU20170041A7 (es) 2014-09-26 2017-09-06 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
EP3389714A4 (fr) 2015-12-14 2019-11-13 MacroGenics, Inc. Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific molecules that bind CD137 and cancer antigens and their uses
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
IL302613A (en) * 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
WO2019160904A1 (fr) 2018-02-15 2019-08-22 Macrogenics, Inc. Domaines variants de liaison à cd3 et leur utilisation en polythérapies pour le traitement d'une maladie
CN112218686A (zh) 2018-04-11 2021-01-12 印希比股份有限公司 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
TW202016151A (zh) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TW202033218A (zh) * 2018-12-07 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 多特異性蛋白分子
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
KR20210006637A (ko) * 2019-07-09 2021-01-19 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (fr) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Anticorps ciblant et autres modulateurs de l'antigène cd276 et leurs utilisations
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
CN117751145A (zh) * 2021-04-28 2024-03-22 礼进生物医药科技（上海）有限公司 包括抗b7h3结合分子的双特异性抗体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311A (zh) * 2024-03-20 2024-04-19 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170779A1 (es) * 2010-03-04 2017-07-04 Macrogenics Inc Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
SI2714733T1 (sl) * 2011-05-21 2019-06-28 Macrogenics, Inc. CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (fr) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
WO2017062619A2 (fr) * 2015-10-08 2017-04-13 Macrogenics, Inc. Polythérapie pour le traitement du cancer

Also Published As

Publication number Publication date
PH12018500363A1 (en) 2018-09-10
CN107921130A (zh) 2018-04-17
TW201718652A (zh) 2017-06-01
WO2017030926A1 (fr) 2017-02-23
AU2016307955A1 (en) 2018-03-08
EP3337507A1 (fr) 2018-06-27
JP2018523686A (ja) 2018-08-23
CR20180105A (es) 2018-06-12
ECSP18011248A (es) 2018-04-30
EP3337507A4 (fr) 2019-04-24
EA201890443A1 (ru) 2018-09-28
CA2995709A1 (fr) 2017-02-23
CL2018000422A1 (es) 2018-08-10
IL257562A (en) 2018-04-30
KR20180038045A (ko) 2018-04-13
ZA201800955B (en) 2018-11-28
PE20181066A1 (es) 2018-07-04
MX2018001954A (es) 2018-11-09
CO2018001485A2 (es) 2018-07-10
HK1249423A1 (zh) 2018-11-02
US20190002563A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MA42665A (fr) Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA47612A (fr) Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
MA43186A (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
HK1226000A1 (zh) 能夠結合gpa33和cd3的雙特異性單價雙抗體及其用途
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
SMT201600392B (it) Anticorpi bispecifici diretti contro cd3epsilon e bcma
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
MA50618A (fr) Polyrhérapies et leurs utilisations
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
IL251377B (en) Monovalent bispecific antibodies that bind 19cd and 3cd, and their use
DK3334824T3 (da) Pd-1-antistoffer
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
AP2016009029A0 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof
DK3122781T3 (da) Bispecifikke antistoffer, der binder til cd38 og cd3
MA55044A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations